Millions of Americans are afflicted by obesity and type 2 diabetes mellitus. Obesity is characterized by increased body adiposity and leads to insulin resistance. Paradoxically, some conditions that are characterized by a paucity of fat also cause insulin resistance, namely the syndromes of lipoatrophy (Fig. 1) . The resemblance between the metabolic abnormalities of these two extreme states of adiposity emphasizes the importance of fat tissue in energy homeostasis. This review focuses on the syndromes of lipodystrophy and lipoatrophy that are at the lean extreme of the spectrum and which are characterized by near-complete absence of fat.
Lipoatrophy syndromes comprise a heterogeneous cluster of disease states having in common a lack of fat tissue [1] . The deficiency of adipose tissue can be partial or generalized, and these abnormalities may be congenital or acquired [1] . The characteristic loss of fat is known as "lipoatrophy" whereas an abnormal distribution of fat is "lipodystrophy". The term "lipoatrophic diabetes" refers to patients who have diabetes mellitus in association with lipoatrophy. It is important to realize that lipodystrophy is a generalized term that encompasses lipoatrophy and other abnormalities of adipose tissue such as lipedema or lipomatosis. In this review, we focus on syndromes characterized primarily by adipocyte deficiencies throughout the body. Although it is important to describe the amount and distibution of adipose tissue, there is also a distinction between the actual insuffiency of adipocytes and preadipocytes that results in metabolic disturbances and those states of total body fat deficiency caused by decreased triglyceride storage. In the latter state, the adipocytes are still basically normal, but are chronically forced to mobilize their stored triglycerides (e.g. under conditions of chronic caloric depletion, intense exercise or increased sympathetic drive [2] [3] [4] [5] ). In all cases of lipoatrophy there is adipocyte insufficiency and the metabolic consequences are peripheral insulin resistance and hypertriglyceridemia. It is also interesting to note that experimental approaches that completely ablate white adipose tissue lead to the metabolic syndrome regardless of the strategy (see below). These observations underscore the importance of the adipocyte not only as storage site for triglycerides; but also as a cell which is capable of sensing nutrient availability and abundance and responding with signals that play a regulatory role in energy storage and partition.
Mechanisms of Disease
Lipodystrophy and lipoatrophy syndromes are characterized by decreased adipose tissue. The congenital forms demonstrate a reduction in adipose tissue throughout life. The proposed mechanism for these forms of lipodystrophy/lipoatrophy results from defects in adipocyte differentiation and function. In the acquired syndromes there is evidence of normal adipocyte development but then a loss of adipose tissue later in life which implies a mechanism of adipocyte destruction. The reduction of adipocytes may occur via decreased growth and differentiation, increased apoptosis, or enhanced destruction as may occur in autoimmune destruction.
In order to better understand possible etiologies of lipodystrophy/lipoatrophy syndromes, it is important to understand normal adipocyte growth and differentiation (Fig. 2) . Normal adipose tissue develops in multiple sites throughout the body from embryonic mesenchymal cells. Over the last decade, there have been great advances in understanding the differentiation program of adipocytes. Precursor cells are committed to adipogenesis through transient expression of certain transcription factors such as the CCAAT/enhancer binding proteins (C/EBPs) and Peroxisome proliferator activating receptors (PPARs) [6] . Other transcription factors are also involved either in activating these key factors or controlling the synthesis E-mail: eliforal@umich.edu of their ligands (for example sterol regulatory elementbinding protein SREBP1/ adipocyte determination and diffrentiation-dependent factor 1 ADD1 may regulate synthesis of ligands for PPARγ [7, 8] ).
Fig. 2. Adipocyte diffrentiation. Mesenchymal precursor cells are committed to the adipogenic pathway in an early step that involves transient expression of the transcription factors C/EBP
Through expression of these nuclear transcription factors, the cell differentiates into an adipocyte and develops the ability to store triglycerides, repress cell-cycle genes and secrete adipocyte-specific hormones. Recently, a novel molecule called lipin has been cloned as a result of positional cloning efforts to identify the genetic etiology of a naturally occurring mouse model with partial lipoatrophy and fatty liver. This novel protein has nuclear localization and is induced during adipocyte differentiation [9] . Its exact role in the adipocyte differentiation pathway remains to be identified.
Defects in adipocyte differentiation commitment steps may lead to adipocyte deficiency; however, the exact control of normal adipocyte growth and cell cycle are not yet fully understood. Furthermore, as we will discuss later on in this review, identification of some of the genes responsible from known human lipoatrophy syndromes did not easily fit the known pathways in adipocyte differentiation.
Another mechanism by which to lose adipocytes is through increased destruction of these cells (such as induction of apoptosis). Animal models of lipoatrophy have been engineered via either distruption of adipogenesis or induction of adipocyte-death. These models help us understand the pathophysiology of fat loss. Some of these models use an adipose-specific promoter/enhancer to introduce a transgene. A review on animal models of lipoatrophy can be found elsewhere [10] .
When discussing the mechanisms of disease in lipoatrophy syndromes, it is important to recognize that the primary event is adipocyte deficiency and that the metabolic problems associated with the syndromes are secondary. The circumstantial evidence for this supposition was based on the similarity of the metabolic phenotype in a wide range of human syndromes. However, the direct proof came with the demonstration that the metabolic phenotype was largely reversed upon fat transplantation in a genetically engineered rodent model of lipoatrophy [11] . Why does fat transplantation reverse metabolic phenotype of lipoatrophy? One hypothesis stresses the endocrine function of the adipocyte. The discovery of the adipocyte hormone leptin underscored the endocrine function of adipose tissue. Leptin communicates body energy stores to the neuroendocrine system to control food-intake and energy expenditure. Leptin has effects (direct or indirect) on the key organs of metabolism, including the liver, muscle and pancreas. Another molecular signal originating from the adipocytes, ACRP 30 [12] (also called adipoQ [13] , APM1 or Adiponectin [14] ) was found to be important in inducing fat oxidation in the muscle and liver [12] . The list of endocrine signals originating from the adipocyte is likely to increase (see review by Lustig in this issue). Lack of adipocytes results in deficiency of these signals, thus contributing to many of the abnormalities seen in these syndromes characterized by absence of fat. Thus, it is possible to view the metabolic aspects of the lipoatrophy syndromes as a consequence of the hormonal insufficiency created by the absence of the organ producing the hormone.
Classification of Lipoatrophy Syndromes
As mentioned above, absence of fat can be partial or generalized. and the syndrome can manifest at birth or later in life [15] . If fat loss is partial, the residual fat undergoes compensatory hypertrophy. Usually, there is a rough correlation between the severity of metabolic consequences and the degree of fat loss. There is also an entity called focal lipoatrophy where the loss of fat involves a single region in the body. One example of this are the loss of fat in the gluteal area usually following intramuscular injections [16] . Therapy with protein hormones, such as insulin [17, 18] and growth hormone [19] may lead to focal lipoatrophy. A focal lipoatrophy may also occur on the face referred to as the Romberg's syndrome [20] . There are other specifically described fat distributions reported in the literature as 'annular" or "semicircular" lipoatrophy [21, 22] . Usually, the isolated loss of fat from a limited body region is not associated with metabolic consequences, supporting the hypothesis that a crucial degree of fat loss is required to observe the metabolic abnormalities.
Genetic Syndromes of Lipoatrophy and Lipodystrophy

Primary lipoatrophy syndromes
Congenital generalized lipoatrophy (Fig. 3) . This condition is also known as Seip-Berardinelli syndrome [23, 24] . In this syndrome, children present with generalized absence of fat within the first year of life. This is followed by insulin resistance, acanthosis nigricans and diabetes mellitus before the teen-age years. Hypertriglyceridemia is severe and is accompanied by frequent bouts of pancreatitis. Affected patients have a high basal metabolic rate [25] and an increased appetite. Circulating leptin levels are usually quite low [26] [27] [28] . This syndrome has an autosomal recessive mode of inheritance, and has been described in all ethnic groups. We have observed a sexual dimorphism in the severity of metabolic complications. Female patients manifest diabetes and hypertriglyceridemia much earlier and usually more severely than the male siblings in the same family. Although well described clinically for decades, the molecular basis for congenital generalized lipoatrophy remained a mystery until quite recently. In the 1970s Foss et.al. demonstrated the presence of a urinary lipolytic factor in cases of congenital generalized lipoatropy; however, these studies have not been reproduced [29] .
Initial work to identify the genetic cause of congenital generalized lipoatrophy started with candidate gene approach. The list of excluded genes was long, including genes encoding peroxisome-proliferator activated receptor-gamma, beta-3-adrenergic receptor, leptin, leptin receptor and lipoprotein lipase among others [30] [31] [32] .
Progress to identify the disease genes came with positional cloning studies. The disease was initially mapped to chromosome 9q34 in some, but not all pedigrees [33] . Thus, it became evident that there were multiple causative genes. Magre et. al. cloned the first gene responsible from congenital generalized lipoatrophy using positional cloning and interval refining [34] . This gene is located on chromosome 11q13. This new gene was named Seipin as an attribute to Seip who is one of the first to describe the syndrome. The protein product of the Seipin gene is most likely a signaling molecule. It has three trans-membrane domains and the ligand is not known. The mouse orthologue of the gene is a G-protein related receptor gene [34] . Contrary to the predictions that prevailed prior to the discovery of this gene, Seipin is not abundantly expressed in the fat cells. It is expressed predominantly in the central nervous system and especially in the pituitary. Another location where it is expressed in high levels is the testes. This localization outside of adipose tissue implies a greater role for the central nervous system in energy storage and fuel metabolism than has currently been known and is likely to change our views on adipocyte differentiation mechanisms [34] .
More recently, the second gene located on chromosome 9q34 was also cloned: 1-acylglycerol-3-phosphate Oacyltransferase 2 (AGPAT2) gene, AGPAT2 gene. AGPAT-2 is a 278 amino acid protein, belonging to the family of acyltransferases and catalyzes an essential reaction in the biosynthetic pathway of glycerophospholipids and triacylglycerol in eukaryotes, namely the conversion of lysophosphatidic acid to phosphaditic acid [35] . Congenital generalized lipodystrophy is the first documented human disease due to a genetic defect in this pathway. The exact cause of lipoatrophy is not clear, but we can formulate some hypotheses. First, the aberrant AGPAT2 enzyme may cause lipodystrophy by resulting in "triglyceride-depleted adipocytes". However, it is important to note that engineered defects in rodents that interfere with triglyceride storage alone and result in "empty" adipocyte syndrome, do not lead to the metabolic consequences so long as the other functional capabilities (like endocrine function) of the adipocytes are not altered [36] . It is also likely that reduced AGPAT2 activity could increase tissue levels of lysophosphatidic acid, which may affect important adipocyte functions [37, 38] . Lysophosphatidic acid is a ligand for G protein coupled receptors and may have a role in preadipocyte proliferation and adipogenesis [37] [38] [39] . Decreased AGPAT2 activity could also lead to reduced bioavailability of phosphatidic acid and phosphoglycerols (phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine), which are important in intracellular signaling and could affect adipocyte functions [40] . Future studies are needed to understand the exact mechanism of lipodystrophy seen with mutations in AGPAT-2. Another interesting question is whether overactivation of this enzyme can be a causative factor for human obesity.
There is also interest in identifying phenotypic differences between the patients harboring mutations on the different genes. First of all, there are some ethnic differences. So far, patients with Labenese descent have mutations exclusively on the Seipin gene and African American patients only have mutations on the AGPAT-2 gene. Mental retardation has been reported in some patients with Seipin mutations and not with AGPAT-2 mutations. Further work in this area may elucidate these differences and may shed some light on the biological function of these two genes.
There are still a few pedigrees with congenital generalized lipoatrophy who do not demonstrate mutations in either of these identified genes. Research is underway to identify other gene(s) responsible from congenital generalized lipoatrophy. Rajab et al. reported observations on 17 patients with congenital generalized lipodystrophy in Oman which suggested the existence of a rare form of the disorder [41] . All children had widespread absence of adipose tissue from infancy together with apparent muscle hypertrophy and hepatomegaly. The patients did not appear to represent a single homogeneous entity, and could be subclassified into 2 distinct groups. In the first group of 7 cases, the features were similar to other published cases with acanthosis nigricans, raised insulin levels, and insulin resistance. In this group there was an association between the degree of acanthosis nigricans and the severity of the disorder. Molecular analysis of these cases showed homozygosity for a mutation at the Berardinelli Seip Congenital Lipodystrophy 2 (BSCL2) locus on 11q13 in 4 of the 7 cases. In the second group of 10 cases, there were striking abnormalities in both skeletal and nonskeletal muscle, including reduced exercise tolerance, and percussion myoedema. None of these children had insulin resistance or early endocrine abnormalities. All 10 had hypertrophic pyloric stenosis operated on in the first 6 weeks of life. The veins were very prominent (phlebomegaly) in the skin and cutis marmorata was present. Cardiac abnormalities with cardiac hypertrophy and arrhythmias were features later in childhood. There was a history of sudden death in some of the sibs. There was evidence against homozygosity in some cases for the known loci of BSCL, and Rajab et. al. suggested that this group may represent a new clinical syndrome with lipodystrophy at a different locus [41] .
Familial partial lipodystrophy (FPLD, Dunnigan's syndrome) (Fig. 4) . Also referred as KobberlingDunnigan syndrome, this condition is inherited in an autosomal dominant fashion. It has been seen mostly in Caucasians of Northern European descent, but pedigrees of Asian descent have also been described. It is usually impossible to distinguish affected patients from unaffected ones before the onset of puberty. Patients are born with normal fat distribution but notice loss of subcutaneous fat in the extremities and trunk with early puberty. This is followed by increased fat in the face and neck as puberty is completed [42, 43] . The visceral fat and interfascicular intramuscular fat depots are preserved [44, 45] . While the disease affects both sexes, the phenotype is much easier to discern in females leading to ascertainment bias of female probands. Overall, female patients develop diabetes and dyslipidemia earlier and more severely. For example, from our case series, affected females develop diabetes about 73% of the time and hypertriglyceridemia 90% of the time. In contrast, these incidences are 36% and 45% respectively, in affected male individuals. Our observations are similar to published observations of another group [46] .
An exciting advance in the understanding of the syndrome has been the discovery that the disease is caused by mutations in the lamin A/C gene (LMNA) located at 1q21-23 [47] [48] [49] [50] [51] . Lamin A and C are alternatively spliced products of the same gene and are ubiquitously, but not equally expressed [52] . They belong to a family of intermediate filament proteins that form the nuclear matrix [53, 54] , which is located just inside the nuclear membrane. Lamins dimerize and oligomerize within the structure of the nuclear matrix [54] . There is developmental regulation of the expression of lamins in humans.
Besides Dunnigan's FPLD, multiple other diseases are associated with mutations in LMNA: Emery Dreyfus muscular dystrophy (a progressive muscular dystrophy of upper and lower extremity muscles with prominent contractures of ankles and elbows, and cardiac conduction abnormalities) [55, 56] , hereditary limb-girdle muscular dystrophy [57] , a familial cardiomyopathy associated with conduction abnormalities [58, 59] , hereditary CharcotMarie Tooth Neuropathy type 2 [60] and finally another complex syndrome with partial lipodystrophy mandibuloacral dysplasia [61] . The degree of overlap between these diseases and FPLD is subject of research. In addition, how the mutations in the LMNA result in multiple different diseases and how the mutations in a ubiquitously expressed gene cause various syndromes with a strong regional distribution are questions still awaiting answers. As far as FPLD is concerned, investigation of expression patterns of various lamins in different adipose depots (visceral versus subcutaneous) did not provide any clues into the mechanism of disease of FPLD [62] . Likewise, investigation of the nuclear targeting or interaction with dimerization partner emerin in a common mutant form seen in FPLD did not elucidate any abnormalities [63] .
Partial lipodystrophy associated with dominant negative mutations on PPAR-gamma gene (late-onset familial partial lipodystrophy). Barroso and colleagues described two probands with severe insulin resistance and hypertension as well as severe acanthosis nigricans [64] . Initially, no changes in body composition were reported. However, careful body composition studies revealed that these patients have significant fat loss in the lower extremities, particularly in the buttock region. The onset of fat loss is not at birth, but develops sometime in adulthood. There is also increased visceral adiposity. Agarwal and Garg described another female patient with a different mutation on PPAR-γ gene who had a similar body fat distribution without any hypertension and acanthosis nigricans [65] . These observations suggest that dominant-negative mutations of the PPAR-γ gene result in both severe insulin resistance and also an abnormality in body fat distribution that manifests later in life.
Congenital syndrome complexes associated with lipoatrophy
There are also other complex monogeneic syndromes that are not characterized as primary lipodystrophy syndromes but are associated with abnormal body fat distribution among other complex abnormalities. Progeria syndromes such as Werner's (adult progeria syndrome, Figure 5 (a), [66] and Cockayne's Syndrome (one of the juvenile progeria syndromes) [67, 68] , carbohydratedeficient glycoprotein syndrome Type 1 [69] , SHORT syndrome (an acronym for short stature, hyperextensibility, hernia, ocular depression, Rieger anomaly and teething delay) [70, 71] and mandibuloacral dysplasia (Fig. 4(b) ) [72, 73] are among such syndromes. AREDYLD syndrome (acral, renal and ectodermal dysplasia in association with generalized lipodystrophy) [74] probably represents another complex progeria syndrome.
Mandibuloacral dysplasia (MAD, Figure 5(b) ) is a genetic disorder with multi-system involvement and autosomal recessive inheritance. This extremely rare syndrome is characterized by multiple skeletal abnormalities, acroosteolysis, joint and skin problems and is also associated with lipodystrophy and metabolic abnormalities [72, 73] . In this condition, the predominant fat loss is from the extremities and trunk with increased visceral adiposity [75] . Recently Novelli et al. analyzed five consanguineous Italian families and demonstrated linkage of MAD to chromosome 1q21, by use of homozygosity mapping. They then sequenced the LMNA gene and identified a homozygous missense mutation (R527H) that was shared by all affected patients [61] . Patient skin fibroblasts showed nuclei that presented abnormal lamin A/C distribution and a dysmorphic envelope, thus demonstrating the pathogenic effect of the R527H LMNA mutation [61] .
Some unusual congenital associations such as Vitamin D resistance and persistent Mullerian ducts [76] , retinal pigmentation abnormalities [77] and sensorineural deafness [78] have been reported in association with lipoatrophy in isolated cases. These unusual patients present as pediatric patients or young adults.
In our case series, we have encountered an autosomal dominant form of congenital lipodystrophy (characterized by absence of fat from face, upper trunk, arms and below the knees) associated with a progressive neurodegenerative disorder (characterized by progressive spinocerebellar ataxia, pyramidal weakness and spasticity, and autonomic insufficiency) and congenital cataracts. In this small pedigree, affected individuals also have insulin resistance and dyslipidemia and both the neurodegenerative disorder and dyslipidemia are more severe in affected female members [79] .
Acquired Syndromes of Lipoatrophy
Syndromes of acquired generalized lipoatrophy are hard to categorize due to the apparent heterogeneity of case reports. As it is clear from the genetic syndromes, certain genetic defects do not manifest an abnormality until a certain point in life. Hence some genetic syndromes can present as so-called "acquired" syndromes. Especially, in the case of recessive disorders, the proband may be the only affected patient and it may be difficult to tease out a genetic pattern of inheritence. Though there are two eponyms used in the literature to describe acquired generalized and acquired partial lipodystrophy syndromes, we will use the descriptive names rather than the eponyms for these syndromes until better molecular tools enable us to categorize these syndromes precisely.
Fig. 4. Dunnigan's familial partial lipodystrophy. (Top) Pictures of a 26-year old female. Note increased fat around the face/neck (A) and deficiency in the gluteal region and lower extremities (B). (Bottom) T1-weighted magnetic resonance images. Transverse sections of the torso at the level of the fifth lumbar vertebra demonstrate markedly deficient subcutaneous and increased visceral fat (C). Transverse sections of the midthigh demonstrate absence of subcutaneous fat with preservation of deep, intrafascicular and marrow fat (D).
Acquired generalized lipoatrophy
Lawrence described acquired generalized lipoatrophy with the onset of the disease during childhood [80] . His original report remains an excellent description of generalized lipoatrophy. Fat loss is usually a remarkable event leading to a dramatic change in physical features (Fig. 6) . The median time to develop diabetes after loss of fat tissue is about 4 years. Both basal metabolic rate and hepatic glucose output are increased. While it is known that these patients lack fully differentiated adipocytes, it is not clear whether they also lack adipocyte precursors [81] . Patients with this type of lipodystrophy may have very severe fat loss, including retroorbital fat and supportive fat in their hands, feet and genital area. Bone marrow fat is lost in some cases, while preserved in others.
Acquired partial lipodystrophy
The case reports that refer to Barraquer-Simons syndrome describe a wide-range of variation with few shared features. Patients usually are women in their second or third decades, who also have a well described autoimmune disorder such as scleroderma or glomerulonephritis, presenting with partial fat loss, [15, 82, 83] . Fat loss usually starts from the face and descends downward until the gluteal line. There is usually increased adiposity in unaffected fat depots (lower extremities). The prevalence of diabetes and hypertriglyceridemia is about 50% in these cases and seems to coseggragate with lower total body fat in our series.
Other associated conditions
Some cases of acquired lipodystrophy occur in the presence of a population of circulating autoantibodies or an association with another autoimmune disease (e.g. juvenile dermatomyositis) and therefore are thought to be autoimmune in nature. There is a clear association of lipodystrophy with juvenile dermatomyositis [84] [85] [86] [87] . These patients typically present before teen-age years. The fat loss can be both generalized or partial. There is usually increased visceral fat despite very severe preipheral fat loss 
. (A) Werner's Syndrome in a 37-year old woman. Clinical features evident include premature aging, allopecia, scleroderma-like changes in the skin and peripheral lipoatrophy as shown. Insulin-resistant diabetes is an associated feature. (B) Mandibuloacral dysplasia in a 14 year old girl. This rare recessive syndrome is characterized by acroosteolysis, widened sutures, hypoplastic mandible (shown) and clavicles (shown). Marked peripheral lipoatrophy and insulin resistance are associated features.
and a specific asymmetric pattern of fat loss on extremities (Fig. 7) .
Panniculitis, a chronic (as defined by lasting 3 months or longer), generalized inflammation of the subcutaneous tissue, has been observed either clinically or proven by biopsy to proceed the loss of fat in some cases of lipodystrophy [88] . The evidence for long-sought specific anti-fat cell autoantibodies or specific activated T-cell clones is still weak A portion of acquired lipodystrophy patients are demonstrated to have low C3 levels [89] and it was speculated that adipsin, a factor produced by fat cells was responsible for the loss of fat due to alternative activation of complement pathway. Generalized or partial fat loss has been described in association with familial [90] or acquired hypocomplementemia [91] [92] [93] .
Some patients infected with HIV while being aggressively treated with protease inhibitors, develop a partial lipoatrophy. The characteristic loss of subcutaneous fat occurs in the face, extremities and trunk. In contrast, visceral fat increases and a "buffalo hump" like that is seen in Cushing syndrome develops [94] [95] [96] . The lipodystrophy is accompanied by the development of insulin resistance and hypertriglyceridemia. The changes in body composition and metabolic parameters are usually apparent within 3 to 6 months of therapy. There is a quicker onset of this partial lipoatrophy when more than one protease inhibitor is used. The syndrome is recognized in both sexes and in pediatric as well as adult patients. Why do treated HIV patients develop this characteristic phenotype? One hypothesis is that an aspartyl protease (like the HIV protease) may be important in the differentiation of adipocytes. In support of this hypothesis, several groups reported that protease inhibitors blocked preadipocyte differentiation in vitro [97, 98] . Interestingly, some groups have reported the development of a similar phenotype when HIV-infected patients are treated aggressively with other antiretroviral agents other than protease inhibitors
Fig. 6. Acquired generalized lipoatrophy. The patient had completely normal fat distribution at age 3 8/12 years old (left) and acutely lost her body fat with a febrile illness at age around age 6 (shown on the right).
(including nucleoside analogues) [99] [100] [101] . This suggests that the lipodystophy may be related to aggressively treated HIV infection rather than to a specific therapy [99, 102] . Further investigations are underway to better categorize the fat tissue changes and metabolic consequences during HIV therapy. While the HIV related lipodsytrophy is the most prevalent form of lipodystrophy, the details of this unique syndrome is not in the scope of this review.
Clinical Abnormalities Observed in Lipoatrophy/Lipodystrophy Syndromes: A Recapitulation of Shared Features (Table 2)
Different syndromes of lipodystrophy have a heterogeneous clinical presentation; however, findings of insulinresistance and hypertriglyceridemia are seen in all forms of lipoatrophy. A greater loss of adipose tissue is associated with an increased severity of the metabolic abnormalities. The insulin resistance leads to hyperinsulinemia, and the associated clinical features of acanthosis nigricans and hyperandrogenism in female patients.
The reproductive abnormalities are more complicated than simple hyperandrogenism and polycystic ovaries in the patients with more severe forms of lipoatrophy. About 50% of all the patients with generalized lipoatrophy and the majority of the female patients (85%) present with very low LH levels, more consistent with hypogonadotropic hypogonadism. This creates a paradox with the findings on ovarian imaging studies since these usually reveal enlarged, polycystic ovaries. Hence, it appears that severe hyperinsulinemia in the most severe cases of lipoatrophy is sufficient to drive the ovarian enlargement and associated hyperandrogenism without any apparent stimulation from the pituitary [103] .
Patients with early-onset hyperinsulinemia (as in congenital generalized lipoatrophy) develop acromegaloid features with soft tissue hyperplasia, somatomegaly and bony abnormalities [104] . Cardiomyopathy is also described in some of these cases [105, 106] .
Another notable finding in the most severely fat deficient patients is their food-seeking behavior. They may consume large amounts of food (similar to patients with bulimia) and get the urge to eat frequently. This behavior is associated with low levels of circulating leptin which may contribute to the increased appetite [28] .
Diabetes will develop in the setting of long-standing hyperinsulinemia due to beta-cell failure. Diabetic retinopathy, nephropathy, neuropathy, gastroparesis as well as coronary heart disease are seen in these patients with uncontrolled and longstanding hyperglycemia.
Fig. 7. A case with severe juvenile dermatomyositis and generalized lipodystrophy. The physical appearance of the 19-year old patient is presented (right). She has severe loss of both muscle and fat tissue. T1-weighted magnetic resonance images of the patient are also presented (left). Transverse sections of the torso at the level of the fifth lumbar vertebra demonstrate markedly deficient subcutaneous and markedly increased visceral fat (top). Transverse sections of the midthigh demonstrate asymmetrical absence of subcutaneous fat with preservation of medial subcutaneous fat and marrow fat (bottom).
There is a high incidence of proteinuria leading to chronic renal failure among patients with lipoatrophy syndromes. While diabetic nephropathy seem to play a role in some of these patients, it does not account for all the cases [107] . The patients with hypocomplementemia develop membranous glomerulonephritis [108] . Focal segmental glomerulosclerosis and tubular lipidosis are also among various kidney pathology that have been described in association with lipoatrophy [109] .
Patients with lipoatrophy have a dyslipidemia that is primarily characterized by elevated triglycerides. This is thought to be secondary to decreased storage site for triglycerides. There is also strong evidence from animal models that lipid synthesis is paradoxically increased in the liver possibly due to decreased signal coming from the adipocyte that "sufficient" lipid storage is achieved. Leptin may be this crucial signal since this abnormality gets corrected in one animal model of lipoatrophy upon leptin replacement [110] .
Most patients have a low HDL and some may have a high LDL. Particularly, the patients with one type of partial lipodystrophy, namely familial partial lipodysrophy of the Dunnigan type have elevated LDL and a markedly increased risk of coronary artery disease [111] .
It is thought that due to a relative paucity of adipose tissue, there is excessive accumulation of triglycerides in multiple locations, most notably in the liver and to some extent in the muscle [112] . Increased deposition of fatty acids and triglycerides in the muscle or in the beta-cell may be responsible for causing insulin resistance (lipotoxicity) [113] [114] [115] . It is possible that the accumulation of triglycerides in hepatocytes causes the injury associated with non-alcoholic steatohepatitis (NASH) [116] . In patients will all types of lipoatrophy there is an increased incidence of non-alcoholic steatohepatitis (NASH) compared to both the diabetic and general population. This condition is seen in at least a third of patients with lipoatrophy and may progress into end-stage liver failure.
We have previously observed that the respiratory quotient (RQ) is elevated in patients with lipoatrophy/ lipodystrophy [117] . The RQ is the ratio of carbon dioxide production to oxygen consumption and reflects the relative contributions of carbohydrates and fat in providing fuel for metabolism. The elevated RQ suggests that there is an increase in fuel consumption relative to synthesis. Therefore, either the rate of fatty acid oxidation is decreased or the rate of lipogenesis is increased. Either change might contribute to the observed elevation in the levels of free fatty acids and triglycerides [118] . Furthermore, because fatty acids are known to antagonize insulin's effects upon glucose metabolism, this provides another mechanism to account for the state of insulin resistance [119] .
Treatment of Lipoatrophy/Lipodystrophy
The clinical problems requiring treatment in lipoatrophy syndromes are diabetes, hypertriglyceridemia and cosmetic problems. The cosmetic problems are quite severe especially for the female patients and can be emotionally scarring. It is important not to underestimate the cosmetic issues while taking care of the metabolic problems. In patients with lower bady fat abundance and upper body fat loss, local fat implantation taken from the area of excess and implanted to the face have produced satisfying results. Facial silicon implants in a few patients with HIV-lipodystrophy have also produced successful cosmetic recovery. It is important to understand patients' expectations and wishes and referral to a plastic surgery center with academic interest in the syndromes may be valuable.
Treatment of diabetes in lipoatrophy
Although there are several classes of anti-diabetic drugs marketed in the U.S., it is difficult to achieve good glycemic control (glycated hemoglobin <7.2%) in most of the patients with lipoatrophic diabetes. There are five groups of pharmaceuticals available to treat diabetic patients [120] all of which may be used to treat lipoatrophic patients: insulin secretagogues, biguanides (metformin), thiazoladienediones (pioglitazone, rosiglitazone), intestinal enzyme inhibitors (acarbose), and insulin itself.
Insulin. Because of their severe insulin resistance, it is frequently necessary to administer extremely high doses (e.g., in excess of 1000 units per day) in patients with various syndromes of lipoatrophy [121] . The volume of injections are more difficult to tolerate in younger patients. Nevertheless, insulin remains the only approved medication for treatment of children with diabetes. Insulin secretagogues. The principal mechanism of action for this class of drugs is to promote insulin secretion by beta cells [122] . Because patients with isolated insulin resistance may not have an independent defect in insulin secretion, sulfonylureas are frequently ineffective in patients with lipoatrophic diabetes.
Metformin. This drug works primarily through inhibiting heptic glucose output. We (and others) have observed that it may help to decrease insulin requirements in some patients with lipoatrophy/ lipodystrophy. To our knowledge, there are no systematic trials looking at the efficacy of this drug in lipoatrophy/lipodystrophy. While the pediatric experience with metformin is growing, it was only recently approved by the U.S Food and Drug Administration to be used in children over the age of 10. Therefore, it needs to be administered by clinicians who have prior experience with treatment with this drug, ideally in centers specialized in treating children with unusual forms of diabetes.
Acarbose. This drug interferes with GI absorption of many carbohydrates [123] . While we are not aware of systematic studies of the efficacy of this drug in patients with lipoatrophy, it has relatively limited efficacy to decrease glucose levels in type 2 diabetes mellitus.
Thiazolidinediones. This class is the newest addition to oral hypoglycemic agents. Members of this class are agonists of peroxisome-proliferator activated receptorgamma (PPAR-gamma); thereby, stimulating adipocyte differentiation [124] . In vivo, this class of drugs functions as insulin-sensitizers and increase insulin-stimulated glucose uptake by the muscle [125, 126] . Troglitazone was the first member to be approved by the US Food and Drug Administration. These effects of thiazolidinedione compounds seemed ideally suited to treat the problems encountered in lipoatrophy/lipodystrophy syndromes. In addition, troglitazone exerted favorable effects in an animal model of lipoatrophy [127] . We thus undertook a treatment trial in these patients with troglitazone [117] . The primary end-points were metabolic control and adipose tissue mass. Six months of troglitazone therapy led to significant improvement in metabolic control with a reduction in HbA1c, triglycerides, and free fatty acids [117] . In addition, there was a small, but statistically significant increase in body fat [117] . Interestingly, the increase was predominantly in the subcutaneous compartment. Furthermore, body weight did not change significantly and there was a decrease in liver size [117] . Despite the favorable effects of troglitazone, the FDA withdrew troglitazone from the US market in March 2000 due to concerns over hepatotoxicity. The newer members of the class, rosiglitazone and pioglitazone, remain in clinical use. The preclinical studies with these two medications suggested that they did not have the same risk of hepatotoxicity. Since the use of thiazolidinediones require judicious monitoring for sideeffects, their use should be supervised by clinicians who are experienced in administering these medications after careful assessment of risk: benefit ratio.
Treatment of dyslipidemia in lipoatrophy
The dyslipidemia of severe lipoatrophy is difficult to treat with the currently available therapeutic interventions which still results in significant morbidity and mortality from this condition. Patients with triglyceride levels over 1000 mg/dl are at risk of developing acute pancreatitis. Recurrent episodes lead to pancreatic insufficiency. Chronically elevated triglycerides in the setting of hyperinsulinemia and low HDL increase the predisposition for coronary artery disease. Severely elevated triglycerides may lead to eruptive painful cutaneous xanthomata [128] .
Troglitazone was remarkable in its ability to improve hypertriglyceridemia in addition to improving glycemia. As niacin is known to worsen glycemic control, we prefer to use fibrates and statins in these severely insulin resistant lipoatrophic patients. Both fibrates and statins may need to be used in combination with careful monitoring for side-effects. Again, the pediatric experience with these medications are extremely limited.
Limitation of caloric intake may be useful for shortterm results, but is not possible to implement for longterm management as dietary fat is required for proper growth and development. Medium chain triglycerides and fish oil have not been tested in a systematic fashion, but may prove to be useful. We have attempted to use intestinal lipase inhibitors in a few of the most severely affected pediatric patients with some positive results. Finally, we have employed long-term plasmapheresis in one patient with extreme hypertriglyceridemia with moderate clinical success [128] .
Leptin replacement therapy: From the laboratory to clinical trials
As mentioned earlier, the metabolic abnormalities of diabetes and hypertriglyceridemia in lipoatrophy may be caused by the absence of hormones produced by fat cells. Shimomura et al. administered one such hormone, leptin, to lipoatrophic mice. Prior to therapy, these mice exhibited diabetes, hypertriglyceridemia, hepatic steatosis and severe leptin deficiency. Interestingly, 3 weeks of leptin therapy ameliorated all the metabolic abnormalities and also decreased the degree of steatosis in the liver [129] . These results from animal models warranted a clinical trial which was recently published.
In the published portion of the trial [28] , 9 female patients with various forms of lipodystrophy (5 with congenital generalized, 3 with acquired generalized and 1 with Dunnigan's familial partial lipodystrophy) were treated with 4 months of subcutaneous leptin administered to achieve physiological concentrations of leptin. Leptin levels increased from a mean of <2 ng/mL to a mean of 12 ng/mL, indicating that that the goal of leptin replacement was largely achieved. There was a remarkable decrease in both hyperglycemia and hypertriglyceridemia as well as improved total body insulin sensitivity and decreased liver volumes (Table 3 ). In addition, the reproductive abnormalities were studied in 7 of these patients. Leptin therapy corrected the amenorrhea seen in 5 of the 5 patients with intact reproductive systems and normalized the attenuated LH response to LHRH stimulation [103] . This leptin-replacement study is likely to inspire similar studies using replacement of adipocyte-specific hormones to treat metabolic abnormalities. Leptin therapy corrects metabolic abnormalities to a great extent in the majority of the patients. However, leptin is certainly not the only hormone made by adipocytes. In fact, in one animal model of lipoatrophy, combined replacement of both leptin and adiponectin result in better metabolic control compared to leptin alone [130] . Haque et al. recently reported that patients with most severe forms of lipodystrophy are deficient in adiponectin levels in addition to leptin [131] . Hence, combined replacement appears as a rational approach when recombinant adiponectin is available for human studies.
Conclusions
Human lipodystrophy syndromes encompass a heterogenous spectrum of disorders characterized by loss of body fat and associated with severe insulin resistance and hypertriglyceridemia. Studies undertaken to search the molecular etiologies of these syndromes have uncovered three completely unexpected genes. Currently researchers are trying to place these genes on known paradigms of adipocyte differentiation. All these gene products are also potential targets for developing novel therapies against the 21st century epidemic, obesity. On the other hand, pathophysiological and therapeutic studies carried out in patients with these disorders and in animal models have taught important lessons about the importance of fat tissue in maintaining normal insulin sensitivity. It is now clear that the adipocyte is an endocrine organ, playing a critical role in glucose and lipid metabolism.
